Q-omics provides the consensus-scored RAD9B profile across patient tissues and cancer cell-line models. RAD9B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RAD9B is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, RAD9B RNA expression shows 18,660 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KICH, and THYM as cancer lineages where RAD9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD9B survival associations across molecular data types. RAD9B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD9B RNA expression–survival associations across cancer types. High RAD9B expression shows unfavorable associations in KIRP and UCEC, but favorable associations in CESC, UCS, KIRC and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for RAD9B RNA expression.
This table summarizes RAD9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RAD9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD9B shows lower tumor expression in KICH, THCA, UCEC and LUAD and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher RAD9B RNA expression in normal versus tumor tissue (log2 FC = −0.877, t-test p < 0.001).
This table shows molecular features associated with RAD9B in patient tissues and cancer cell lines. In patient samples, RAD9B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD9B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
